+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Colistin Sulfate for Humans Market by Route of Administration (Intravenous, Oral), End User (Ambulatory Care Centers, Clinics, Hospitals), Distribution Channel, Indication, Formulation, Strength - Global Forecast 2025-2030- Product Image
Colistin Sulfate for Humans Market by Route of Administration (Intravenous, Oral), End User (Ambulatory Care Centers, Clinics, Hospitals), Distribution Channel, Indication, Formulation, Strength - Global Forecast 2025-2030- Product Image
New

Colistin Sulfate for Humans Market by Route of Administration (Intravenous, Oral), End User (Ambulatory Care Centers, Clinics, Hospitals), Distribution Channel, Indication, Formulation, Strength - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6131789
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Colistin sulfate has re-emerged as a critical antibiotic in the human therapeutic armamentarium, driven by the alarming rise in multidrug-resistant Gram-negative infections. First discovered in the mid-20th century, this polymyxin antibiotic catalyzed a paradigm shift in treating pathogens impervious to conventional treatments. However, safety concerns and the development of less toxic alternatives led to its waning use in the 1970s and 1980s. Today, as resistance escalates and fewer novel antibiotics reach the market, colistin sulfate’s potency against carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa has rekindled clinical interest. This resurgence underscores its role as a last-resort therapy, with healthcare providers balancing efficacy against potential nephrotoxicity and neurotoxicity.

This executive summary elucidates the evolving landscape of colistin sulfate for human use, providing an integrated overview of key market dynamics, emerging clinical evidence, and strategic considerations. By contextualizing scientific advances in formulation, regulatory developments, and market segmentation, decision-makers can harness actionable intelligence to optimize development pathways and meet pressing patient needs. Ultimately, a nuanced understanding of this antibiotic’s repositioning will guide stakeholders through complex treatment protocols and competitive environments.

Unveiling Fundamental Paradigm Shifts in Colistin Sulfate Application Fueled by Novel Delivery Innovations and Regulatory Framework Evolutions

Recent years have witnessed transformative shifts in the way colistin sulfate is delivered, regulated, and integrated into clinical protocols. Advances in formulation science have produced both powder for injection and solution variants that improve dosing precision and stability, allowing clinicians to tailor therapy for diverse patient populations. Simultaneously, stringent regulatory frameworks have emerged globally, emphasizing robust pharmacovigilance and quality manufacturing practices to mitigate safety risks. These evolving compliance standards have incentivized manufacturers to invest in advanced analytics and process controls, elevating the overall reliability of the supply chain.

Beyond formulation and regulation, the landscape has been reshaped by novel delivery innovations and stewardship initiatives. Intravenous and oral administration routes are being optimized through enhanced formulation matrices and patient support programs, while antimicrobial stewardship efforts are promoting judicious prescribing practices that preserve therapeutic efficacy. Collectively, these shifts are redefining how colistin sulfate is perceived by healthcare providers, payers, and patients, fostering an environment that prioritizes both scientific rigor and responsible use.

Assessing Projected United States Tariff Implications for Colistin Sulfate Market Dynamics and Global Supply Chain Resilience Strategies in 2025

The imposition of new tariffs by the United States in 2025 has introduced a complex dimension to the global colistin sulfate value chain. As major manufacturing hubs in Asia adjust to higher import duties, the cost dynamics of raw materials and finished products have been significantly disrupted. This has compelled stakeholders to revisit sourcing strategies, exploring alternative procurement arrangements and nearshoring options to maintain continuity of supply and manage cost pressures.

In response to these policy changes, industry players are forging strategic partnerships and contractual collaborations with domestic and regional distributors. By diversifying manufacturing footprints and leveraging tariff mitigation mechanisms, life science companies are safeguarding access to critical antimicrobial therapies. Concurrently, healthcare providers and payers are recalibrating contracting models and reimbursement frameworks to accommodate evolving pricing structures. In doing so, the ecosystem strives to ensure that patient access remains uninterrupted despite geopolitical and fiscal headwinds.

Dissecting Comprehensive Segmentation Insights Covering Administration Routes, End Users, Distribution Channels, Indications, Formulations, and Strength Variants

An in-depth analysis of colistin sulfate reveals nuanced performance across multiple segmentation dimensions, each influencing strategic decision making. When examining the route of administration, the intravenous format dominates acute care settings by enabling direct bloodstream delivery for severe infections, while the oral route offers potential advantages in outpatient and step-down scenarios. Concerning end users, hospitals remain the primary demand center due to intensive care unit requirements, with clinics and ambulatory care centers increasingly adopting outpatient protocols that extend therapy beyond hospital walls.

Distribution channels demonstrate a heterogeneous mix of hospital pharmacies, online pharmacies, and retail pharmacies. Within the retail segment, chain pharmacies leverage centralized procurement efficiencies, whereas independent pharmacies provide localized services and personalized patient support. Therapeutic indications further differentiate market needs: complicated urinary tract infections necessitate high-concentration dosing regimens, hospital acquired pneumonia protocols require strict dosing schedules, and skin and soft tissue infections benefit from flexible administration matrices. Formulation choices between powder for injection and solution variants drive considerations around storage stability, reconstitution time, and handling protocols. Strength gradations of 150,000 IU per milliliter versus 250,000 IU per milliliter grant clinicians dosing flexibility tailored to pathogen susceptibility and patient tolerance profiles. Holistically, these segmentation insights equip stakeholders with a granular understanding of demand drivers and treatment pathways.

Evaluating Regional Dynamics Influencing Colistin Sulfate Adoption and Market Priorities Across Americas, Europe Middle East Africa, and Asia Pacific Regions

Regional dynamics exert a profound influence on colistin sulfate utilization and strategic priorities. In the Americas, robust healthcare infrastructures and advanced antimicrobial stewardship frameworks have accelerated the adoption of colistin sulfate, with market participants emphasizing compliance with stringent safety monitoring and dosing guidelines. The region’s emphasis on precision medicine has also spurred investment in companion diagnostics to optimize treatment outcomes.

Across Europe, the Middle East & Africa, a mosaic of regulatory regimes and healthcare systems has led to divergent market trajectories. Western European nations maintain rigorous approval processes and pharmacovigilance mandates, while emerging markets in the Middle East and North Africa navigate access challenges through targeted public health initiatives. Stakeholders in this region are actively collaborating with governmental agencies to streamline regulatory harmonization and reinforce supply chain resilience.

In Asia-Pacific, a dual focus on manufacturing capabilities and expanding patient access is evident. Major production centers in East and South Asia are scaling capacity to serve both domestic and export markets, while Southeast Asian countries are enhancing distribution networks to improve rural and urban healthcare reach. Policymakers and industry leaders are jointly exploring public-private partnerships to fortify procurement strategies and ensure continuity of lifesaving therapies.

Highlighting Competitive Strategies, Portfolio Diversification, and Innovation Trajectories Among Leading Colistin Sulfate Manufacturers and Strategic Alliances

Leading manufacturers of colistin sulfate have deployed multifaceted strategies to maintain competitive positions and drive innovation. These players are diversifying portfolios beyond generic offerings by investing in research collaborations that explore novel polymyxin derivatives and combination therapies. Strategic alliances with academic institutions and biotech firms are enhancing R&D pipelines, enabling the development of next-generation formulations that improve patient safety and therapeutic efficacy.

To strengthen market presence, companies are optimizing manufacturing processes through continuous improvement frameworks and quality by design principles. This emphasis on manufacturing excellence yields consistent product performance and mitigates regulatory risks. Concurrently, corporate partnerships and licensing agreements are facilitating entry into underserved markets, leveraging established distribution networks to expand geographic reach. Collaborative agreements with contract manufacturing organizations and distribution specialists further underscore the importance of an integrated value chain. Collectively, these competitive maneuvers reinforce industry resilience and lay the groundwork for sustained growth in a dynamic antibiotic landscape.

Delivering Actionable Strategic Recommendations to Empower Industry Leaders in Optimizing Colistin Sulfate Development, Distribution, and Stakeholder Engagement

Industry leaders can capitalize on emerging opportunities by adopting a proactive, integrated approach across the colistin sulfate lifecycle. First, expanding manufacturing capacity through strategic investments in modular and flexible production facilities will mitigate supply constraints and address potential tariff impacts. Next, fostering end-to-end supply chain transparency via digital traceability platforms enhances risk management and supports compliance with evolving regulatory demands.

In parallel, accelerating clinical research to refine dosing algorithms and safety monitoring protocols can unlock new label extensions and optimize patient outcomes. Engaging healthcare stakeholders through targeted educational initiatives will reinforce appropriate prescribing practices and strengthen antimicrobial stewardship efforts. Furthermore, forging collaborative partnerships across the value chain, including alliances with diagnostic developers and logistics providers, will streamline distribution pathways and improve market access. Finally, leveraging real-world evidence and advanced analytics in post-market surveillance will inform continuous product improvement and establish a data-driven culture that drives long-term therapeutic success.

Elucidating Rigorous Research Methodology Incorporating Systematic Data Collection, Analytical Frameworks, and Validation Processes for Market Insights

The research methodology underpinning this analysis integrates systematic data collection, robust primary research, and meticulous validation protocols to ensure comprehensive and reliable market intelligence. An extensive literature review of peer-reviewed journals, regulatory publications, and technical whitepapers established foundational insights into colistin sulfate’s clinical applications and policy frameworks. This desk research was complemented by in-depth interviews with key opinion leaders, including infectious disease specialists, pharmacologists, and supply chain experts, to capture firsthand perspectives on therapeutic trends and operational challenges.

Quantitative data sets from public health agencies, manufacturing registries, and trade databases were triangulated to corroborate findings and identify patterns across geographies and market segments. Advanced analytical frameworks, such as SWOT and PESTEL analyses, provided multidimensional evaluations of competitive landscapes and external drivers. Throughout the research process, rigorous quality control measures, including data accuracy audits and cross-verification by independent analysts, were implemented to uphold methodological integrity. This hybrid approach delivers a holistic, evidence-based foundation for strategic decision making.

Synthesizing Key Insights and Strategic Implications to Illuminate Future Trajectories and Collaborative Opportunities within the Colistin Sulfate Landscape

In synthesizing the diverse insights presented, it is clear that colistin sulfate occupies a pivotal role in addressing multidrug-resistant infections within a complex global healthcare ecosystem. The confluence of formulation innovations, evolving regulatory landscapes, and strategic supply chain adaptations underscores the antibiotic’s renewed clinical relevance. Stakeholders who harness granular segmentation intelligence and regional dynamics will be better positioned to navigate market challenges and patient needs.

The interplay between competitive strategies, actionable recommendations, and rigorous methodological underpinnings offers a roadmap for sustained therapeutic impact. By embracing collaborative alliances and data-driven practices, decision-makers can optimize development programs, enhance patient outcomes, and fortify market resilience. Ultimately, a cohesive, forward-looking plan will catalyze the responsible expansion of colistin sulfate use, ensuring that this critical therapy remains accessible and effective in the battle against antimicrobial resistance.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Intravenous
    • Oral
  • End User
    • Ambulatory Care Centers
    • Clinics
    • Hospitals
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
      • Chain Pharmacies
      • Independent Pharmacies
  • Indication
    • Complicated Urinary Tract Infections
    • Hospital Acquired Pneumonia
    • Skin And Soft Tissue Infections
  • Formulation
    • Powder For Injection
    • Solution
  • Strength
    • 150000 Iu/Ml
    • 250000 Iu/Ml
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Mallinckrodt Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Fresenius Kabi AG
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Aurobindo Pharma Ltd.
  • Lupin Ltd.
  • Cipla Ltd.
  • Mylan N.V.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increased use of colistin sulfate in combination therapies for multidrug resistant infections
5.2. Rising regulatory scrutiny and stewardship programs limiting colistin sulfate prescriptions
5.3. Growth of generic colistin sulfate formulations driving competitive pricing dynamics
5.4. Advances in injection delivery methods enhancing colistin sulfate treatment adherence
5.5. Regional market expansion in Asia Pacific due to rising antibiotic resistance rates
5.6. Ongoing clinical trials evaluating colistin sulfate safety profiles in pediatric populations
5.7. Emergence of colistin sulfate inhalation therapies addressing cystic fibrosis lung infections
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Colistin Sulfate for Humans Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
9. Colistin Sulfate for Humans Market, by End User
9.1. Introduction
9.2. Ambulatory Care Centers
9.3. Clinics
9.4. Hospitals
10. Colistin Sulfate for Humans Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.4.1. Chain Pharmacies
10.4.2. Independent Pharmacies
11. Colistin Sulfate for Humans Market, by Indication
11.1. Introduction
11.2. Complicated Urinary Tract Infections
11.3. Hospital Acquired Pneumonia
11.4. Skin And Soft Tissue Infections
12. Colistin Sulfate for Humans Market, by Formulation
12.1. Introduction
12.2. Powder For Injection
12.3. Solution
13. Colistin Sulfate for Humans Market, by Strength
13.1. Introduction
13.2. 150000 Iu/Ml
13.3. 250000 Iu/Ml
14. Americas Colistin Sulfate for Humans Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Colistin Sulfate for Humans Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Colistin Sulfate for Humans Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Mallinckrodt Pharmaceuticals
17.3.2. Hikma Pharmaceuticals PLC
17.3.3. Fresenius Kabi AG
17.3.4. Dr. Reddy’s Laboratories Ltd.
17.3.5. Teva Pharmaceutical Industries Ltd.
17.3.6. Sandoz International GmbH
17.3.7. Aurobindo Pharma Ltd.
17.3.8. Lupin Ltd.
17.3.9. Cipla Ltd.
17.3.10. Mylan N.V.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. COLISTIN SULFATE FOR HUMANS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2024 VS 2030 (%)
FIGURE 16. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. COLISTIN SULFATE FOR HUMANS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. COLISTIN SULFATE FOR HUMANS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. COLISTIN SULFATE FOR HUMANS MARKET: RESEARCHAI
FIGURE 28. COLISTIN SULFATE FOR HUMANS MARKET: RESEARCHSTATISTICS
FIGURE 29. COLISTIN SULFATE FOR HUMANS MARKET: RESEARCHCONTACTS
FIGURE 30. COLISTIN SULFATE FOR HUMANS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. COLISTIN SULFATE FOR HUMANS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY POWDER FOR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY POWDER FOR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY 150000 IU/ML, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY 150000 IU/ML, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY 250000 IU/ML, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY 250000 IU/ML, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 89. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 90. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 91. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 96. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 97. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 100. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 101. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 102. CANADA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 103. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 110. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 111. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 112. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 113. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 114. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 115. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 116. MEXICO COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 175. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 182. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 183. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 186. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 187. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 188. GERMANY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 189. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 196. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 197. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 198. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 199. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 200. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 201. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 202. FRANCE COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 203. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 217. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 224. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 225. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 226. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 227. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 228. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 229. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 230. ITALY COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 231. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 238. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 239. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 242. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 243. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 244. SPAIN COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 287. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 294. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 295. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 296. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 297. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 298. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 299. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 300. DENMARK COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 301. NETHERLANDS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. NETHERLANDS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. NETHERLANDS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. NETHERLANDS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. NETHERLANDS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. NETHERLANDS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. NETHERLANDS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 308. NETHERLANDS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 309. NETHERLANDS COLISTIN SULFATE FOR HUMANS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 310. NETHERLANDS

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Colistin Sulfate for Humans market report include:
  • Mallinckrodt Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Fresenius Kabi AG
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Aurobindo Pharma Ltd.
  • Lupin Ltd.
  • Cipla Ltd.
  • Mylan N.V.

Related Topics

Related Reports

Colistin Sulfate Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Colistin Sulfate Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 89 Pages
  • Global
From
Colistin Sulphate Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Colistin Sulphate Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 83 Pages
  • Global
From
Peptide Antibiotics Market by Product (Bacitracin, Colistin, Daptomycin), Route Of Administration (Intramuscular, Intravenous, Oral), Formulation, Source, Application, End Use, Distribution Channel - Global Forecast 2025-2030 - Product Image

Peptide Antibiotics Market by Product (Bacitracin, Colistin, Daptomycin), Route Of Administration (Intramuscular, Intravenous, Oral), Formulation, Source, Application, End Use, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Polymyxin B Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application - Product Image

Polymyxin B Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application

  • Report
  • 94 Pages
  • Global
From
Bacterial Enzymes as Targets for Drug Discovery. Meeting the Challenges of Antibiotic Resistance. Foundations and Frontiers in Enzymology - Product Image

Bacterial Enzymes as Targets for Drug Discovery. Meeting the Challenges of Antibiotic Resistance. Foundations and Frontiers in Enzymology

  • Book
Copyright © 2002-2025 Research and Markets. All Rights Reserved.